Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $56
Kymera Therapeutics Analyst Ratings
Oppenheimer Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $60
Leerink Partners Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $60
Kymera Therapeutics Price Target Announced at $65.00/Share by Wolfe Research
Wolfe Research Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Announces Target Price $65
Kymera Therapeutics Analyst Ratings
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Maintains Target Price $45
Kymera Therapeutics Analyst Ratings
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $45
Balancing Pipeline Potential and Clinical Risks: Kymera Therapeutics' Strategic Update and Hold Rating
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Kymera Therapeutics (KYMR) and Viridian Therapeutics (VRDN)
Kymera Therapeutics Analyst Ratings
Wells Fargo Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $38
Optimistic Buy Rating for Kymera Therapeutics Amid Promising Clinical Developments
Kymera Therapeutics (KYMR) Gets a Buy From TD Cowen
Kymera Therapeutics Analyst Ratings
Oppenheimer Maintains Outperform on Kymera Therapeutics, Maintains $52 Price Target
B. Riley Securities Maintains Neutral on Kymera Therapeutics, Raises Price Target to $36